SCHEMBL6597147

SCHEMBL6597147

COc1cc(C(=O)N(C)CC(CCN2CCCN(c3nc4ccccc4n3CC(F)(F)F)CC2)c2cccc(Cl)c2)cc(OC)c1OC

nearest known ligand 0.42

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TACR2 P21452 11/20 0.42
CCR5 P51681 5/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6596863 0.94 TACR2 (0.41) TACR2
SCHEMBL6595439 0.93 TACR2 (0.52) TACR2
SCHEMBL6591422 0.92 TACR2 (0.40) TACR2CCR5
SCHEMBL6595980 0.92 TACR2 (0.40) TACR2CCR5
SCHEMBL6597944 0.92 TACR2 (0.43) TACR2CCR5
SCHEMBL6595777 0.91 TACR2 (0.51) TACR2CCR5
SCHEMBL6593743 0.91 TACR2 (0.40) TACR2
SCHEMBL6596565 0.91 LMNA (0.43) TACR2
SCHEMBL6602898 0.90 HRH1 (0.43) TACR2CCR5
SCHEMBL6595611 0.90 TACR2 (0.42) TACR2CCR5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0888338-B1 NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES AVENTIS PHARMA INC (US) 2004-11-17 EP disclosed
EP-0888338-A1 NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1999-01-07 EP disclosed
WO-1997030991-A1 NOVEL SUBSTITUTED N-METHYL-N-(4-(4-(1H-BENZIMIDAZOL-2-YL)[1,4]DIAZEPAN-1-YL)-2-(ARYL)BUTYL)BENZAMIDES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES HOECHST MARION ROUSSEL, INC. (US) 1997-08-28 WO disclosed